Related Experiment Video
Updated: Apr 8, 2026
05:31
Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
1.5K
OS050. Genetic variants in pre-eclampsia: a meta-analysis.
A Buurma1, R Turner1, A Driessen2
1Pathology, Leiden University Medical Center, Leiden, Netherlands.
Pregnancy Hypertension
|June 25, 2015
Summary
This study identified 8 genetic variants reproducibly associated with preeclampsia, primarily in the renin-angiotensin and coagulation systems. These findings suggest shared genetic risk factors between preeclampsia and cardiovascular disease.
Area of Science:
- Genetics
- Obstetrics
- Cardiovascular Medicine
Background:
- Preeclampsia exhibits a familial component, indicating a potential genetic susceptibility.
- Numerous genetic association studies exist, but replication has been inconsistent.
- This meta-analysis focuses on reproducibly associated genetic variants in preeclampsia.
Purpose of the Study:
- To provide an overview of genetic variants reproducibly linked to preeclampsia.
- To consolidate findings from multiple genetic association studies.
Main Methods:
- A systematic literature search was conducted in PubMed, EMBASE, and Web of Science.
- Genetic variants significantly associated in an initial study and reproduced in at least one other study were selected.
- Pooled odds ratios were calculated at the allele level for the association between variants and preeclampsia.
Main Results:
- 542 genetic association studies on preeclampsia were identified from 2965 citations.
- 23 genetic variants were found to be replicated.
- A random-effects meta-analysis confirmed 8 variants significantly associated with preeclampsia, located in or near ACE, AGT, CTLA4, F2, FV (two variants), LPL, and SERPINE1 genes.
Conclusions:
- Eight genetic variants are associated with preeclampsia, predominantly in the renin-angiotensin and coagulation systems.
- Shared genetic risk factors between preeclampsia and cardiovascular disease are indicated.
- Future research should explore the role of these identified genes in preeclampsia pathogenesis.
More Related Videos
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
119
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
119
01:29Pharmacogenomics: Identification of New Drug Targets
88
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
88
01:27Principles of Pharmacogenetics: Types of Genetic Variants
106
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
106
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
01:11Genome-wide Association Studies-GWAS
16.8K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
16.8K
01:27Pharmacogenetics of Drug Metabolism: Overview
137
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
137